Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: Effect of treatment with lanreotide Autogel and consequence of treatment withdrawal

European Journal of Endocrinology

Volumn 162, Issue 5, 2010, Pages 993-999

  Auriemma, Renata S ^a   Galdiero, Mariano ^a   Grasso, Ludovica F S ^a   Vitale, Pasquale ^a   Cozzolino, Alessia ^a   Lombardi, Gaetano ^a   Colao, Annamaria ^a   Pivonello, Rosario ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GADOLINIUM PENTETATE; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CASE REPORT; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HEMIANOPIA; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; REMISSION; TREATMENT DURATION; TUMOR VOLUME; VISUAL FIELD;

ACROMEGALY; ADENOMA; FEMALE; HUMANS; MIDDLE AGED; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; REMISSION INDUCTION; SOMATOSTATIN;

EID: 77951660832     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0769     Document Type: Article

References (38)

1. Melmed S. Acromegaly. New England Journal of Medicine 2006 355 2558-2573.
2. Colao A, Auriemma RS, Pivonello R, Galdiero M & Lombardi G. Medical consequences of acromegaly: what are the effects of biochemical control? Reviews in Endocrine & Metabolic Disorders 2008 9 21-31.
3. Freda PU. How effective are current therapies for acromegaly? Growth Hormone and IGF Research 2003 13 144-151.
4. Burt M & Ho K. Comparison of efficacy and tolerability of somatostatin analogues and other therapies for acromegaly. Endocrine 2003 20 299-306. (Pubitemid 36571033)
5. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S & Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2112-2118. (Pubitemid 43854991)
6. Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocrine Reviews 2004 25 102-152. (Pubitemid 38269977)
7. Murray RD & Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. Journal of Clinical Endocrinology and Metabolism 2008 93 2957-2968.
8. Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1856-1863. (Pubitemid 40464061)
9. Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J & Pagani G. Slow release in the treatment of acromegaly: a study in 66 patients. European Journal of Endocrinology 2000 143 577-584.
10. Ronchi CL, Rizzo E, Lania AG, Pivonello R, Grottoli S, Colao A, Ghigo E, Spada A, Arosio M & Beck-Peccoz P. Preliminary data on biochemical remission of acromegaly after somatostatin analogs discontinuation. European Journal of Endocrinology 2008 158 19-25. (Pubitemid 351211036)
11. Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A & Cozzi R. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 2003 88 5258-5265. (Pubitemid 37452725)
12. Ben-Shlomo A & Melmed S. Somatostatin agonists for treatment of acromegaly. Molecular and Cellular Endocrinology 2008 14 192-198.
13. Lucas T, Astorga R & Catala M. Preoperative lanreotide treatment for GH-secreting adenomas: effect on tumor volume and predictive factors of significant tumor shrinkage. Clinical Endocrinology 2003 58 471-481.
14. Cannavo S, Squadrito S, Curto L, Almoto B, Vieni A & Trimarchi F. Results of a two-year treatment with slow release lanreotide in acromegaly. Hormone and Metabolic Research 2000 32 224-229.
15. Colao A, Martino E, Cappabianca P, Cozzi P, Scanarini M, Ghigo E & ALICE Study Group. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. Journal of Endocrinological Investigation 2006 30 1017-1020.
16. Colao A, Ferone D, Cappabianca P, Del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Calì A, De Divitiis E & Lombardi G. Effect of octreotide pretreatment on surgical outcome in acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 3308-3314.
17. Colao A, Marzullo P, Ferone D, Marinò V, Pivonello R, Di Somma C, Di Sarno A, Giaccio A & Lombardi G. Effectiveness and tolerability of slow-release lanreotide treatment in active acromegaly. Journal of Endocrinological Investigation 1999 22 40-47.
18. van Thiel SW, Romijn JA, Biermasz NR, Ballieux BEPM, Frolich M, Smit JWA, Corssmit EPM, Roelfsema F & Pereira AM. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. European Journal of Endocrinology 2004 150 489-495.
19. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A & Carella C. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clinical Endocrinology 2002 56 65-71.
20. Auriemma RS, Pivonello R, Galdiero M, De Martino MC, De Leo M, Vitale G, Lombardi G & Colao A. Octreotide-LAR vs lanreotide as first-line therapy in acromegaly: a retrospective, comparative head-to-head study. Journal of Endocrinological Investigation 2008 31 956-965.
21. Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, Minuto F, Lombardi G, Pivonello R & Ferone D. Significant tumor shrinkage after 12 months of lanreotide Autogel treatment given first-line in acromegaly. Clinical Endocrinology 2009 71 237-245.
22. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleimberg D & Barkan A. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 4405-4410.
23. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S & Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2112-2118.
24. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A & Caron P. Long-term (up to 18 years) effects on GH/IGF-I hypersecretion and tumor size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clinical Endocrinology 2007 67 282-289.
25. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L & Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Journal of Clinical Endocrinology and Metabolism 2006 91 1397-1403.
26. Attanasio R, Lanzi R, Losa M, Valentini F, Grimaldi F, De Menis E, Davì MV, Battista C, Castello R, Cremonini N, Razzore P, Rosato F, Montini M & Cozzi R. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocrinological Practice 2008 14 846-855.
27. Dasqupta P. Somatostatin analogue: multiple roles in cellular proliferation, neoplasia and angiogenesis. Pharmacology and Therapeutics 2004 102 61-85.
28. Resmini E, Murialdo G, Giusti M, Boschetti M, Minuto F & Ferone D. Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarly treated with octreotide LAR. Journal of Endocrinological Investigation 2005 28 166-169.
29. Livadas A, Hadjidakis DJ, Argyropoulou MI, Stamatelatou M, Kelekis D & Raptis SA. Disappearance of a growth hormone secreting macroadenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal. Hormones 2006 5 57-63.
30. Avramidis A, Polyzos SA, Efstathiadou Z & Kita M. Sustained clinical inactivity and stabilization of GH/IGF-I levels in an acromegalic patient after discontinuation of somatostatin analogue treatment. Endocrine Journal 2008 55 351-357.
31. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleimberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JAH & Giustina A. Consensus statement: medical management of acromegaly. European Journal of Endocrinology 2005 153 737-740.
32. Cannavo S, Squadrito S, Curto L, Almoto B & Trimarchi F. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Hormone and Metabolic Research 2001 33 618-624.
33. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S & Lombardi G. Beneficial effects of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. European Journal of Endocrinology 2007 157 579-587.
34. Mazziotti G & Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010 13 60-67.
35. Hubina A, Nanzer AM, Hanson HR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni MR, Khalaf S, Jordan S, Czirjàk S, Hanzèl YZ, Nagy GM, Gòth MI, Grossman AB & Korboninits M. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumors. European Journal of Endocrinology 2006 155 371-379.
36. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG & Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. European Journal of Endocrinology 1995 133 686-690.
37. Taboada GF, Luque RM, Vieira Neto L, de O Machado E, Sbaffi CB, Domingues RC, Marcondes JB, Chimelli LMC, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD & Gadelha MR. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. European Journal of Endocrinology 2008 158 295-303.
38. Pawlikowski M, Pisarek H, Kunert-Radek J & Radek M. Somatostatin receptors in GH-secreting pituitary adenomas- their relationship to the response to octreotide. Polish Journal of Endocrinology 2008 59 196-199.